Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells with Stem Cell Transplant for High Risk Myeloid Malignancies
NCT01823198Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2013
- Primary completion
- May 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic natural killer cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose-limiting Toxicities at 42 days. Started Jun 2013; status: completed.
02
Drugs
allogeneic natural killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01823198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01823198.